(Q36221979)

12 August 2017

1 reference

title

Haemophilia B: Christmas disease (English)

1 reference

12 August 2017

0 references

0 references

Paul Giangrande

1

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 August 2005

1 reference

Expert Opinion on Pharmacotherapy

12 August 2017

published in

1 reference

12 August 2017

volume

6

1 reference

12 August 2017

issue

9

1 reference

12 August 2017

page(s)

1517-1524

1 reference

Treatment of haemophilia in the United Kingdom 1981-1996.

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1517

21 January 2018

Haemophilias A and B.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1517

The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1517

Six characters in search of an author: the history of the nomenclature of coagulation factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1517

Disruption of a C/EBP binding site in the factor IX promoter is associated with haemophilia B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1517

Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1517

Treatment of hemophilia: recombinant factors only? Yes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1517

Treatment of hemophilia: recombinant factors only? No.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1517

Virus safety of solvent/detergent-treated antihaemophilic factor concentrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1517

Hepatitis A virus infections associated with clotting factor concentrate in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1517

Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1517

The transfusion-associated transmission of parvovirus B19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1517

Nanofiltration of plasma-derived biopharmaceutical products

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1517

Immunization of patients with bleeding disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1517

Risk of variant Creuzfeldt-Jakob disease from factor concentrates: current perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1517

A cross-over pharmacokinetic and thrombogenicity study of a prothrombin complex concentrate and a purified factor IX concentrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1517

Disseminated intravascular coagulation and hemorrhage in hemophilia B following elective surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1517

Myocardial infarction after factor IX therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1517

Use of recombinant factor IX in subjects with haemophilia B undergoing surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1517

The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1517

A survey of factor prophylaxis in the Canadian haemophilia A population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1517

A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1517

Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1517

Prophylaxis in factor IX deficiency product and patient variation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1517

Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1517

Severe allergic pulmonary oedema after plasma transfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1517

Gene deletions in patients with haemophilia B and anti-factor IX antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1517

Management of haemophilia B patients with inhibitors and anaphylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1517

Inhibitors in congenital coagulation disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1517

Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.9.1517

10.1517/14656566.6.9.1517

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference